Susan Sallach, MD
Cardiovascular Disease · Midland, MINPI 1659338630
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,323 of the $1,443 with a category attached, or 91.7%. Abbott accounts for 96.1% of it on its own, with 2 other manufacturers making up the rest. 2024 is the largest year on record at $1,386, more than ten times the $39 reported in 2022. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.
Across 9 payments — averaging $160.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Edwards Lifesciences$39
- GE HealthCare$18
Across 2 payments — averaging $50,555 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$101K
What the payments were for
- Travel & lodging$1,32392%
- Food & beverage$1198%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $1,386 |
| Edwards Lifesciences | 1 | $39 |
| GE HealthCare | 1 | $18 |
How this compares
$1,443 in reported general payments places this provider in the 40th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 612 | $836,040 |
| Repatha SureclickEvolocumab | 176 | $213,324 |
| XareltoRivaroxaban | 97 | $141,260 |
| Praluent PenAlirocumab | 70 | $66,795 |
| MultaqDronedarone Hcl | 21 | $32,889 |
| JardianceEmpagliflozin | 22 | $29,529 |
| EntrestoSacubitril/Valsartan | 15 | $26,503 |
| Bisoprolol Fumarate | 386 | $18,077 |
| Atorvastatin Calcium | 996 | $15,732 |
| Metoprolol Succinate | 602 | $10,476 |
| Rosuvastatin Calcium | 445 | $8,008 |
| Fenofibrate | 14 | $5,491 |
| Losartan Potassium | 402 | $4,770 |
| PradaxaDabigatran Etexilate Mesylate | 22 | $4,585 |
| Ezetimibe | 156 | $3,645 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Midland
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
- Douglas HorstmanshofRoyal Oak$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.